The FDA has approved the first generic versions of AstraZeneca Farxiga, unlocking a massive US market for dapagliflozin API as multiple Indian generics prepare for launch.

Piramal Pharma Solutions and Ajinomoto Bio-Pharma Services have announced a strategic collaboration combining ADC manufacturing expertise with site-specific conjugation technology.

China's drug regulator has suspended imports of several Indian APIs over quality and GMP compliance failures, accelerating a structural reshoring of the global API supply chain that creates new opportunities for diversified suppliers.

Gilead Sciences' $5 billion acquisition of German ADC specialist Tubulis signals a new era in antibody-drug conjugate development, creating unprecedented demand for bioconjugation services, linker-payload technologies, and specialized cytotoxic APIs.